Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / H••••• S••••••• B•••••••

A•••••••• C•••••• P••••••• Portfolio Company Molecular Products Group Announces Acquisition of the H••••• S•••••••® B•••••••

Platform acquisitionannouncedannounced Dec 18, 2018Fact
What happened
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
unknown
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
4 named
Buy side
  • “The acquisition of S••••••• ® further establishes Molecular Products in the strategically important healthcare segment of the business, leveraging the Company’s core chemical technologies and expanding its capabilities,” said P•••• M••••, Managing Partner of A•••••••• C•••••• P•••••••.
  • M•••••• L•••••, a Principal of A••••••••, added, “This acquisition demonstrates Molecular Products’ continued focus on highly strategic M&A to expand the Company’s product offerings and enhance its capabilities across all of its segments.”
  • A•••••••• C•••••• P••••••• Portfolio Company Molecular Products Group Announces Acquisition of the H••••• S•••••••® B••••••• | published on A•••••••• C•••••• P•••••••'s own news page arlingtoncap.com
Side not stated
Evidence
A•••••••• C•••••• P••••••• Portfolio Company Molecular Products Group Announces Acquisition of the H••••• S•••••••® B•••••••